BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Home » Authors » Sergio Held

Articles by Sergio Held

Venezuelan med-tech guild confronts non-responsive government

Feb. 25, 2016
By Sergio Held

Embattled Sientra gets ready to go back to work after certification debacle

Feb. 16, 2016
By Sergio Held
BOGOTA, Colombia — After facing an unprecedented crisis last year, breast implants company Sientra Inc. reported that it is ready to resume its commercial activities next month.
Read More

Looking to Replace traditional syringes :Mexican millennials developing futuristic med-tech products

Feb. 5, 2016
By Sergio Held

Steba enters LatAm, files MAA in Europe for prostate cancer drug

Jan. 28, 2016
By Sergio Held

Steba enters LatAm, files MAA in Europe for prostate cancer drug

Jan. 28, 2016
By Sergio Held
BOGOTA, Colombia – After 12 years in relative stealth mode, Steba Biotech, a Luxembourg-based company owned by Israeli shareholders is launching operations in Latin America and submitted a marketing authorization application (MAA) to the EMA for Tookad, seeking approval to market the drug for the treatment of localized prostate cancer.
Read More

Silimed issues still not resolved: Sientra's new CEO updates physicians over crisis with Brazilian operations

Jan. 13, 2016
By Sergio Held

HPV vaccine under fire in Brazil; MFP files action requesting ban

Jan. 8, 2016
By Sergio Held
BOGOTA, Colombia – Multinational manufacturers of human papillomavirus (HPV) vaccines are getting ready to defend the effectiveness of the product in Brazil after a public attorney set out to ban them across the country.
Read More

Eurofarma looking for opportunities to expand into Africa, Asia, U.S.

Dec. 30, 2015
By Sergio Held
BOGOTA, Colombia – Brazilian pharma major Eurofarma is looking to expand its footprint by tapping into markets in Africa, investing in the U.S. and reaching deeper into Latin America markets through new plants, the acquisition of established businesses and by introducing new products.
Read More

Tijuana's med-tech sector enjoyed much success in 2015

Dec. 29, 2015
By Sergio Held

Prostate diagnosis kits: Mdxhealth enters LatAm market with Uruguayan partner Southgenetics

Dec. 22, 2015
By Sergio Held
Previous 1 2 … 13 14 15 16 17 18 19 20 21 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Liver with hepatitis viruses, blood cells

    Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

    BioWorld
    GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing